<DOC>
	<DOCNO>NCT01923558</DOCNO>
	<brief_summary>To evaluate compare relative bioavailability therefore bioequivalence two different formulation donepezil single oral dose administration fast condition .</brief_summary>
	<brief_title>Bioavailability Study Donepezil Hydrochloride Tablets 23 mg Under Fasting Condition</brief_title>
	<detailed_description>Single center , randomize , single dose , laboratory-blinded , 2-period , 2-sequence , crossover study fast condition .</detailed_description>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Male female volunteer 2 . Volunteer age least 18 year old 45 year 3 . Volunteer body mass index ( BMI ) great equal 21 30 kg/m2 4 . Volunteer body weight great equal 60 kg . 5 . Light , non exsmokers . A light smoker define someone smoking 10 cigarette less per day least 3 month day 1 study . An exsmoker define someone completely stop smoke least 12 month day 1 study . 6 . Availability entire study period 7 . Motivated volunteer absence intellectual problem likely limit validity consent participate study compliance protocol requirement ; ability cooperate adequately ; ability understand observe instruction physician designee . 8 . Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance 9 . Have clinically significant disease capture medical history evidence clinically significant finding physical examination and/or clinical laboratory evaluation ( hematology , biochemistry , ECG urinalysis ) 10 . Willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date volunteer Exclusion Criteria 1 . Seated pulse rate le 50 bpm screen 2 . Seated blood pressure 105/60 mmHg screen 3 . Seated blood pressure 105/60 mmHg drug administration 4 . Females pregnant lactate 5 . Females childbearing potential refuse use acceptable contraceptive regimen throughout entire duration study 6 . History significant hypersensitivity donepezil , piperidine derivative , scopolamine , relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug 7 . Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect 8 . History significant gastrointestinal , liver kidney disease may affect drug bioavailability 9 . Presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic dermatologic disease 10 . Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease 11 . Presence outofrange cardiac interval ( PR &lt; 110 msec , PR &gt; 200 msec , QRS &gt; 110 msec QTc &gt; 440 msec ) screen ECG clinically significant ECG abnormality . 12 . Use ASA NSAIDs ( product contain ASA NSAIDs ) previous 7 day day 1 study 13 . Use diphenhydramine previous 10 hour day 1 study 14 . Known presence rare hereditary problem galactose /or lactose intolerance 15 . Known presence glaucoma predisposition angleclosure glaucoma 16 . Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) 17 . Any clinically significant illness previous 28 day day 1 study 18 . Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin , rifampin St John 's Wort ) , previous 28 day day 1 study 19 . Any history tuberculosis and/or prophylaxis tuberculosis 20 . Positive urine screen alcohol and/or drug abuse 21 . Positive result HIV , HBsAg antiHCV test 22 . Females pregnant accord positive serum pregnancy test 23 . Volunteers take Investigational Product ( another clinical trial ) donate 50 mL blood previous 28 day day 1 study . 24 . Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>